Livforsakringsbolaget Skandia Omsesidigt Buys New Holdings in United Therapeutics Corporation $UTHR

Livforsakringsbolaget Skandia Omsesidigt purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 36,400 shares of the biotechnology company’s stock, valued at approximately $19,702,000.

A number of other large investors have also bought and sold shares of UTHR. Geneos Wealth Management Inc. increased its stake in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 70 shares during the period. Jump Financial LLC purchased a new stake in United Therapeutics during the 2nd quarter valued at $277,000. Cerity Partners LLC grew its holdings in United Therapeutics by 77.3% in the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after acquiring an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia grew its holdings in United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 105 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

UTHR stock opened at $515.46 on Friday. United Therapeutics Corporation has a 1 year low of $303.08 and a 1 year high of $609.35. The firm has a 50-day moving average of $530.46 and a 200 day moving average of $538.70. The company has a market cap of $22.11 billion, a P/E ratio of 18.44, a PEG ratio of 1.79 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the previous year, the firm posted $6.41 EPS. The business’s revenue was down 1.9% on a year-over-year basis. On average, equities research analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on UTHR. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday. Morgan Stanley set a $515.00 target price on United Therapeutics in a research note on Thursday, August 6th. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. JPMorgan Chase & Co. increased their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $646.00.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,311,581.28. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $541.39, for a total value of $5,143,205.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at $21,933,333.07. This represents a 19.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 424,075 shares of company stock valued at $227,336,485 in the last three months. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.